Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Department of Physiology, Anatomy & Genetics (DPAG) have collaborated on an international study that demonstrates a detailed mechanistic understanding of how the anti-malaria drug, Hydroxychloroquine, combined with antibiotics, can cause adverse cardiac side-effects in COVID-19 patients. This gives weight to US Federal advice against using this combined treatment.

Blue and white capsules pill in blister pack arranged neatly together

Hydroxychloroquine (HCQ), a drug normally used to treat malaria, has recently been touted as a potential treatment for coronavirus. International interest in the drug was raised following reports of US President Donald Trump taking the drug to ward off COVID-19 and there have been clinical trials in several countries testing its effectiveness. However, many scientists have warned about side effects of using HCQ, which has led to the World Health Organisation temporarily suspending several studies over safety fears. 

Recent reports on the use of HCQ alone, or combined with an antibiotic called azithromycin (AZM), in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have specifically raised concerns over cardiac safety. However, so far little has been known about the mechanisms behind HCQ and AZM therapy to help evaluate cardiac safety, and therefore conclusively determine if it is unsafe for the heart.

A new international study, on which the DPAG groups of Professor David Paterson, with Dr Dan Li, and Associate Professor Neil Herring have collaborated, has provided mechanistic insight into how HCQ alone and HCQ with AZM affects cardiac electrophysiology.

Read the full story on the DPAG website

Similar stories

Cancer Research UK to invest £11 million into cancer science in Oxford

A £11 million Cancer Research UK investment has been awarded to the University of Oxford and Oxford-based NHS to catalyse the translation of its world-leading cancer research for patient benefit.

Review highlights risk factors associated with violence in schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

First comprehensive analysis of global impact of antimicrobial resistance (AMR) estimates resistance itself caused 1.27 million deaths in 2019 - more deaths than HIV/AIDS or malaria - and that antimicrobial-resistant infections played a role in 4.95 million deaths.

Attention and memory deficits persist for months after recovery from mild Covid

Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

New book expands the horizons of brain research

A pioneering book from Professor Zoltán Molnár and Yale Professors Tamas Horvath and Joy Hirsch to be released on 1 February 2022 addresses the fundamental relationship between the body, brain and behaviour.